Remus Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹614 crore and net profit of ₹25 crore for the September 2026 quarter.
Remus Pharma. (NSE: REMUS-SM) closed at ₹817.60 on 20 Nov 2026, up 12.4% over the past year. Its market capitalisation is ₹963 crore and it trades at 23.4 times earnings.
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.